{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:51:57Z","timestamp":1792788717192,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Finely tuned mitogen-activated protein kinase (MAPK) signaling is important for cancer cell survival. Perturbations that push cells out of the MAPK fitness zone result in cell death. Previously, in a screen of the North China Pharmaceutical Group Corporation\u2019s pure compound library of microbial origin, we identified elaiophylin as an autophagy inhibitor. Here, we demonstrated a new role for elaiophylin in inducing excessive endoplasmic reticulum (ER) stress, ER-derived cytoplasmic vacuolization, and consequent paraptosis by hyperactivating the MAPK pathway in multiple cancer cells. Genome-wide CRISPR\/Cas9 knockout library screening identified SHP2, an upstream intermediary of the MAPK pathway, as a critical target in elaiophylin-induced paraptosis. The cellular thermal shift assay (CETSA) and surface plasmon resonance (SPR) assay further confirmed the direct binding between the SHP2 and elaiophylin. Inhibition of the SHP2\/SOS1\/MAPK pathway through SHP2 knockdown or pharmacological inhibitors distinctly attenuated elaiophylin-induced paraptosis and autophagy inhibition. Interestingly, elaiophylin markedly increased the already-elevated MAPK levels and preferentially killed drug-resistant cells with enhanced basal MAPK levels. Elaiophylin overcame drug resistance by triggering paraptosis in multiple tumor-bearing mouse models resistant to platinum, taxane, or PARPi, suggesting that elaiophylin might offer a reasonable therapeutic strategy for refractory ovarian cancer.<\/jats:p>","DOI":"10.1038\/s41392-022-01131-7","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T10:03:56Z","timestamp":1662977036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation"],"prefix":"10.1038","volume":"7","author":[{"given":"Guan-Nan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Shi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Nan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Mei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-6294","authenticated-orcid":false,"given":"Xiao-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1332-9230","authenticated-orcid":false,"given":"Jian-Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-3423","authenticated-orcid":false,"given":"Qing-Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"1131_CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan, J., Dong, X., Yap, J. & Hu, J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J. Hematol. Oncol. 13, 113 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"1131_CR2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 103\u2013119 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1131_CR3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"1131_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251\u2013255 (2013).","journal-title":"Nature"},{"key":"1131_CR5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","volume":"17","author":"GP Leung","year":"2019","unstructured":"Leung, G. P. et al. Hyperactivation of MAPK Signaling Is Deleterious to RAS\/RAF-mutant Melanoma. Mol. Cancer Res. 17, 199\u2013211 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1131_CR6","doi-asserted-by":"crossref","first-page":"108928","DOI":"10.1016\/j.celrep.2021.108928","volume":"34","author":"E Cho","year":"2021","unstructured":"Cho, E., Lou, H. J., Kuruvilla, L., Calderwood, D. A. & Turk, B. E. PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. Cell Rep. 34, 108928 (2021).","journal-title":"Cell Rep."},{"key":"1131_CR7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41588-021-00967-z","volume":"53","author":"T Ito","year":"2021","unstructured":"Ito, T. et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nat. Genet. 53, 1664\u20131672 (2021).","journal-title":"Nat. Genet."},{"key":"1131_CR8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong, A. et al. Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discov. 8, 74\u201393 (2018).","journal-title":"Cancer Discov."},{"key":"1131_CR9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Gourley, C., Vergote, I. & Oza, A. M. Epithelial ovarian cancer. Lancet 393, 1240\u20131253 (2019).","journal-title":"Lancet"},{"key":"1131_CR10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"1131_CR11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"1131_CR12","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.428","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi, L. et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 5, e1257 (2014).","journal-title":"Cell Death Dis."},{"key":"1131_CR13","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo, J. et al. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 30, 1437\u20131447 (2019).","journal-title":"Ann. Oncol."},{"key":"1131_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245\u2013251 (2010).","journal-title":"Lancet"},{"key":"1131_CR15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias, M. P., Moser, S. C., Ganesan, S. & Jonkers, J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 18, 773\u2013791 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1131_CR16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccell.2018.06.012","volume":"34","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation. Cancer Cell 34, 315\u2013330 e317 (2018).","journal-title":"Cancer Cell"},{"key":"1131_CR17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.omto.2019.05.005","volume":"14","author":"C Huang","year":"2019","unstructured":"Huang, C. et al. FoxM1 induced paclitaxel resistance via activation of the FoxM1\/PHB1\/RAF-MEK-ERK pathway and enhancement of the ABCA2 transporter. Mol. Ther. Oncolytics 14, 196\u2013212 (2019).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1131_CR18","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","volume":"9","author":"C Sun","year":"2017","unstructured":"Sun, C. et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci. Transl. Med. 9, eaal5148 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1131_CR19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/sj.cdd.4401465","volume":"11","author":"S Sperandio","year":"2004","unstructured":"Sperandio, S. et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1\/Alix. Cell Death Differ. 11, 1066\u20131075 (2004).","journal-title":"Cell Death Differ."},{"key":"1131_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.01.003","volume":"162","author":"D Lee","year":"2016","unstructured":"Lee, D., Kim, I. Y., Saha, S. & Choi, K. S. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol. Ther. 162, 120\u2013133 (2016).","journal-title":"Pharmacol. Ther."},{"key":"1131_CR21","doi-asserted-by":"crossref","first-page":"188338","DOI":"10.1016\/j.bbcan.2020.188338","volume":"1873","author":"F Fontana","year":"2020","unstructured":"Fontana, F., Raimondi, M., Marzagalli, M., Di Domizio, A. & Limonta, P. The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim. Biophys. Acta Rev. Cancer 1873, 188338 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1131_CR22","unstructured":"ARAI, M. Azalomycins B and F, two new antibiotics. J. Antibiot. 13, 46\u201350 (1960)."},{"key":"1131_CR23","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1080\/15548627.2015.1017185","volume":"11","author":"X Zhao","year":"2015","unstructured":"Zhao, X. et al. Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. Autophagy 11, 1849\u20131863 (2015).","journal-title":"Autophagy"},{"key":"1131_CR24","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1146\/annurev.biochem.68.1.913","volume":"68","author":"AC Gingras","year":"1999","unstructured":"Gingras, A. C., Raught, B. & Sonenberg, N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913\u2013963 (1999).","journal-title":"Annu. Rev. Biochem."},{"key":"1131_CR25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/jid.2013.325","volume":"134","author":"A Croft","year":"2014","unstructured":"Croft, A. et al. Oncogenic activation of MEK\/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress. J. Invest. Dermatol. 134, 488\u2013497 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"1131_CR26","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","volume":"20","author":"CR Maroun","year":"2000","unstructured":"Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J. & Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell Biol. 20, 8513\u20138525 (2000).","journal-title":"Mol. Cell Biol."},{"key":"1131_CR27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1097-2765(01)00369-0","volume":"8","author":"W Lu","year":"2001","unstructured":"Lu, W., Gong, D., Bar-Sagi, D. & Cole, P. A. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 8, 759\u2013769 (2001).","journal-title":"Mol. Cell"},{"key":"1131_CR28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"1131_CR29","doi-asserted-by":"crossref","first-page":"11933","DOI":"10.1158\/0008-5472.CAN-07-5185","volume":"67","author":"J Wang","year":"2007","unstructured":"Wang, J., Zhou, J. Y. & Wu, G. S. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 67, 11933\u201311941 (2007).","journal-title":"Cancer Res"},{"key":"1131_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.12.001","volume":"25","author":"G Maik-Rachline","year":"2016","unstructured":"Maik-Rachline, G. & Seger, R. The ERK cascade inhibitors: towards overcoming resistance. Drug Resist Update 25, 1\u201312 (2016).","journal-title":"Drug Resist Update"},{"key":"1131_CR31","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Paraptosis-inducing nanomedicine overcomes cancer drug resistance for a potent cancer therapy. Small 14, 1702446 (2018).","DOI":"10.1002\/smll.201702446"},{"key":"1131_CR32","doi-asserted-by":"crossref","first-page":"101061","DOI":"10.1016\/j.redox.2018.11.019","volume":"21","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells. Redox Biol. 21, 101061 (2019).","journal-title":"Redox Biol."},{"key":"1131_CR33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"1131_CR34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/15384047.2017.1345386","volume":"18","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis. Cancer Biol. Ther. 18, 584\u2013595 (2017).","journal-title":"Cancer Biol. Ther."},{"key":"1131_CR35","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.apsb.2020.07.001","volume":"10","author":"J Zheng","year":"2020","unstructured":"Zheng, J. et al. Targeting castration-resistant prostate cancer with a novel RORgamma antagonist elaiophylin. Acta Pharm. Sin. B 10, 2313\u20132322 (2020).","journal-title":"Acta Pharm. Sin. B"},{"key":"1131_CR36","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/jcp.22956","volume":"227","author":"WB Wang","year":"2012","unstructured":"Wang, W. B. et al. Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J. Cell. Physiol. 227, 2196\u20132206 (2012).","journal-title":"J. Cell. Physiol."},{"key":"1131_CR37","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1021\/acs.jmedchem.6b00484","volume":"59","author":"H Zheng","year":"2016","unstructured":"Zheng, H. et al. Novel benzo[a]quinolizidine analogs induce cancer cell death through paraptosis and apoptosis. J. Med. Chem. 59, 5063\u20135076 (2016).","journal-title":"J. Med. Chem."},{"key":"1131_CR38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.freeradbiomed.2009.12.016","volume":"48","author":"MJ Yoon","year":"2010","unstructured":"Yoon, M. J., Kim, E. H., Lim, J. H., Kwon, T. K. & Choi, K. S. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic. Biol. Med. 48, 713\u2013726 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"1131_CR39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","volume":"10","author":"M Macheret","year":"2015","unstructured":"Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 10, 425\u2013448 (2015).","journal-title":"Annu. Rev. Pathol."},{"key":"1131_CR40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ccell.2015.01.007","volume":"27","author":"PT Schumacker","year":"2015","unstructured":"Schumacker, P. T. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell 27, 156\u2013157 (2015).","journal-title":"Cancer Cell"},{"key":"1131_CR41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371\u2013385.e318 (2018).","journal-title":"Cell"},{"key":"1131_CR42","doi-asserted-by":"crossref","unstructured":"Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science 368, eaaw5473 (2020).","DOI":"10.1126\/science.aaw5473"},{"key":"1131_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong, L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Target Ther. 6, 201 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1131_CR44","first-page":"6250","volume":"45","author":"PA Andrews","year":"1985","unstructured":"Andrews, P. A., Murphy, M. P. & Howell, S. B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res. 45, 6250\u20136253 (1985).","journal-title":"Cancer Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01131-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T16:16:51Z","timestamp":1701015411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-01131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-01131-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}